Sun Pharma announces Winlevi cream available in the US markets


Sun Pharmaceutical Industries today announced the availability of WINLEVI (clascoterone) cream 1% in the United States (US). A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the topical treatment of acne vulgaris in patients 12 years of age and older.

Sun Pharmaceutical Industries was quoting at Rs 791.40, down Rs 3.00, or 0.38 percent on the BSE.

News Source:- Moneycontrol

For Enquiry Fill The Form

    *Note:- Please provide a valid Email Id to receive OTP from

    Facebook Iconfacebook like buttonYouTube IconTwitter Icontwitter follow button